An exome-wide sequencing study of the GOLDN cohort reveals novel associations of coding variants and fasting plasma lipids
JournalFrontiers in Genetics
PublisherFrontiers Media S.A.
MetadataShow full item record
AbstractBackground: Associations of both common and rare genetic variants with fasting blood lipids have been extensively studied. However, most of the rare coding variants associated with lipids are population-specific, and exploration of genetic data from diverse population samples may enhance the identification of novel associations with rare variants. Results: We searched for novel coding genetic variants associated with fasting lipid levels in 894 samples from the Genetics of Lipid Lowering Drugs and Diet Network (GOLDN) with exome-wide sequencing-based genotype data. In single variant tests, one variant (rs11171663 in ITGA7) was associated with fasting triglyceride levels (P = 7.66E-08), explaining approximately 3.2% of the total trait variance. In gene-based tests, we found statistically significant associations between ITGA7 (P = 1.77E-07) and SLCO2A1 (P = 7.18E-07) and triglycerides, as well as between POT1 (P = 3.00E-07) and low-density lipoprotein cholesterol. In another independent replication cohort consisting of 3,183 African American samples from Hypertension Genetic Epidemiology Network (HyperGEN) and the Genetic Epidemiology Network of Arteriopathy (GENOA), the top genes achieved P-values of 0.04 (ITGA7), 0.08 (SLCO2A1), and 0.02 (POT1). In GOLDN, gene transcript levels of ITGA7 and SLCO2A1 were associated with fasting triglycerides (P = 0.07 and P = 0.02), highlighting functional relevance of our findings. Conclusion: In this study, we present preliminary evidence of novel rare variant determinants of fasting lipids, and reveal potential underlying molecular mechanisms. Moreover, these results were replicated in an independent cohort. Our findings may inform novel biomarkers of disease risk and treatment targets. Copyright 2019 Geng, Irvin, Hidalgo, Aslibekyan, Srinivasasainagendra, An, Frazier-Wood, Tiwari, Dave, Ryan, Ordovas, Straka, Feitosa, Hopkins, Borecki, Province, Mitchell, Arnett and Zhi.
SponsorsThe GOLDN study has been funded by the National Institutes of Health (NIH) National Heart, Lung, and Blood Institute (NHLBI) Grants U01HL072524 and R01HL091357. The HAPI Heart Study was supported by NIH grants U01 HL072515 and P30 DK072488. Whole genome sequencing of Amish subjects was provided by the Trans-Omics for Precision Medicine program through the National Heart, Lung and Blood Institute (NHLBI) and funded by 3R01HL121007-01S1, 3R01HL-117626-02S1, and 3R01HL-120393-02S1.
Identifier to cite or link to this itemhttps://www.scopus.com/inward/record.uri?eid=2-s2.0-85065816821&doi=10.3389%2ffgene.2019.00158&partnerID=40&md5=ff92fbcf02c0607a2874fbfc9f110a95; http://hdl.handle.net/10713/10548